BIO Report: Attrition Higher For Novel Pain Candidates Than In Other Diseases, Funding Lacking
A new report released during the BIO CEO conference shows novel pain therapy candidates face a high failure rate, which may help explain why smaller, privately held biotechs aren't very active in the space.
You may also be interested in...
Speaking at the BIO CEO & Investor Conference, US agency's No. 2 official talks about compassionate use, opioids, clinical trial design, and the agency's succession plan.
One of Teva's few bright spots is its leading position in the big new commercial opportunity for migraine, but its CGRP drug fremanezumab could now be delayed by an issue at third-party manufacturer Celltrion.
Commissioner Gottlieb announces several actions in the works to promote development of new treatments for opioid addiction, including guidance on how to establish novel endpoints.